Land: Canada
Sprog: engelsk
Kilde: Health Canada
ZOLMITRIPTAN
TEVA CANADA LIMITED
N02CC03
ZOLMITRIPTAN
1MG
TABLET (ORALLY DISINTEGRATING)
ZOLMITRIPTAN 1MG
ORAL
2/6
Prescription
SELECTIVE SEROTONIN AGONISTS
Active ingredient group (AIG) number: 0134381003; AHFS:
CANCELLED PRE MARKET
2015-10-16
PRODUCT MONOGRAPH PR TEVA-ZOLMITRIPTAN (zolmitriptan) tablets 1 mg and 2.5 mg PR TEVA-ZOLMITRIPTAN OD (zolmitriptan) orally disintegrating tablets 1 mg and 2.5 mg Professed Standard Migraine Therapy 5-HT 1 Receptor Agonist Teva Canada Limited 30 Novopharm Court Toronto, Ontario M1B 2K9 www.tevacanada.com Submission Control No: 176520 Date of Revision: July 31, 2014 2 TABLE OF CONTENTS PRODUCT MONOGRAPH ........................................................................................................ 1 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 11 DRUG INTERACTIONS ......................................................................................................... 18 DOSAGE AND ADMINISTRATION ..................................................................................... 19 OVERDOSAGE ....................................................................................................................... 21 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 21 STORAGE AND STABILITY ................................................................................................. 24 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 24 PART II: Læs hele dokumentet